Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings

Alejandra Maciel, Ali Cullors, Andrew A Lukowiak, Jorge Garces AltheaDx, San Diego, CA, USA Abstract: The burden of depression significantly impacts the patient, the health care system, and society, at large. Medication management guided by pharmacogenetics has been shown to increase therapeutic e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maciel A, Cullors A, Lukowiak AA, Garces J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Pharmacogenetics depression personalized medicine cost-savings pharmacoeconomics psychotropic cytochrome P450 Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4d941f45cf7e49d995b22e26b72b4f95
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d941f45cf7e49d995b22e26b72b4f95
record_format	dspace
spelling	oai:doaj.org-article:4d941f45cf7e49d995b22e26b72b4f952021-12-02T04:41:07ZEstimating cost savings of pharmacogenetic testing for depression in real-world clinical settings1178-2021https://doaj.org/article/4d941f45cf7e49d995b22e26b72b4f952018-01-01T00:00:00Zhttps://www.dovepress.com/estimating-cost-savings-of-pharmacogenetic-testing-for-depression-in-r-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Alejandra Maciel, Ali Cullors, Andrew A Lukowiak, Jorge Garces AltheaDx, San Diego, CA, USA Abstract: The burden of depression significantly impacts the patient, the health care system, and society, at large. Medication management guided by pharmacogenetics has been shown to increase therapeutic efficacy and improve symptoms in patients diagnosed with depression, but limited data are available on the cost savings of pharmacogenetic-guided interventions outside of psychiatric clinical specialties. Our study utilizes published health care costs and clinical patient outcome data to model the economic impact of pharmacogenetic-guided treatment for depression in a variety of clinical settings. Assuming a test cost of USD$2,000 for pharmacogenetic testing, the model predicts a savings of USD$3,962 annually per patient with pharmacogenetic-guided medication management. Keywords: pharmacogenetics, depression, personalized medicine, cost savings, pharmacoeconomics, psychotropic, cytochrome P450Maciel ACullors ALukowiak AAGarces JDove Medical PressarticlePharmacogeneticsdepressionpersonalized medicinecost-savingspharmacoeconomicspsychotropiccytochrome P450Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 225-230 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pharmacogenetics depression personalized medicine cost-savings pharmacoeconomics psychotropic cytochrome P450 Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Pharmacogenetics depression personalized medicine cost-savings pharmacoeconomics psychotropic cytochrome P450 Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Maciel A Cullors A Lukowiak AA Garces J Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
description	Alejandra Maciel, Ali Cullors, Andrew A Lukowiak, Jorge Garces AltheaDx, San Diego, CA, USA Abstract: The burden of depression significantly impacts the patient, the health care system, and society, at large. Medication management guided by pharmacogenetics has been shown to increase therapeutic efficacy and improve symptoms in patients diagnosed with depression, but limited data are available on the cost savings of pharmacogenetic-guided interventions outside of psychiatric clinical specialties. Our study utilizes published health care costs and clinical patient outcome data to model the economic impact of pharmacogenetic-guided treatment for depression in a variety of clinical settings. Assuming a test cost of USD$2,000 for pharmacogenetic testing, the model predicts a savings of USD$3,962 annually per patient with pharmacogenetic-guided medication management. Keywords: pharmacogenetics, depression, personalized medicine, cost savings, pharmacoeconomics, psychotropic, cytochrome P450
format	article
author	Maciel A Cullors A Lukowiak AA Garces J
author_facet	Maciel A Cullors A Lukowiak AA Garces J
author_sort	Maciel A
title	Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
title_short	Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
title_full	Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
title_fullStr	Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
title_full_unstemmed	Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
title_sort	estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/4d941f45cf7e49d995b22e26b72b4f95
work_keys_str_mv	AT maciela estimatingcostsavingsofpharmacogenetictestingfordepressioninrealworldclinicalsettings AT cullorsa estimatingcostsavingsofpharmacogenetictestingfordepressioninrealworldclinicalsettings AT lukowiakaa estimatingcostsavingsofpharmacogenetictestingfordepressioninrealworldclinicalsettings AT garcesj estimatingcostsavingsofpharmacogenetictestingfordepressioninrealworldclinicalsettings
_version_	1718401118161076224

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings

Ejemplares similares